Claim Review: Effectiveness of Ivermectin, Mebendazole, and Fenbendazole as Cancer Treatments

Introduction

A recent article published on October 16, 2024, claims that a peer-reviewed study in the International Journal of Orthomolecular Medicine shows that ivermectin, mebendazole, and fenbendazole are effective treatments for cancer. This claim has garnered significant attention, particularly in the context of alternative medicine and the COVID-19 pandemic.

The Claim

The article asserts that Drs. William Makis, Paul Marik, Ilyes Baghli, and other scientists from the Frontline COVID-19 Critical Care Alliance (FLCCC) have conducted a study demonstrating the anticancer benefits of these three deworming drugs. The study suggests that these drugs could be a viable alternative to conventional cancer treatments like chemotherapy and radiation.

Analysis of the Claim

The study published in the International Journal of Orthomolecular Medicine is indeed peer-reviewed, which lends some credibility to the claim. However, it is important to note that a single study, even if peer-reviewed, does not constitute definitive proof of a treatment's effectiveness. Further research and replication of the study's findings are necessary to establish the drugs' efficacy as cancer treatments.

Ivermectin, mebendazole, and fenbendazole are primarily used as antiparasitic medications. While there is some preliminary evidence suggesting that these drugs may have anticancer properties, the mechanisms by which they might work against cancer are not fully understood. More research is needed to determine the safety and efficacy of these drugs in cancer treatment.

The article also mentions the concept of 'turbo cancer,' which is not a widely recognized medical term. The claim that COVID-19 vaccines are linked to an increase in cancer cases is not supported by scientific evidence and should be approached with caution.

Conclusion

While the study published in the International Journal of Orthomolecular Medicine is a promising development, it is too early to conclude that ivermectin, mebendazole, and fenbendazole are effective cancer treatments. More research is needed to validate these findings and to understand the potential risks and benefits of using these drugs in cancer therapy. Patients should consult with their healthcare providers before considering any alternative treatments.

References

• Ivermectin as a Broad-Spectrum Host-Directed Antiviral: The Real Deal? 
• Mebendazole as a Repurposed Agent in Cancer Therapy 
• Fenbendazole: A Broad-Spectrum Anthelmintic Drug with Potential Anticancer Activity